Simplify Asset Management Inc. Invests $700,000 in Upstream Bio, Inc. $UPB

Simplify Asset Management Inc. bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 77,793 shares of the company’s stock, valued at approximately $700,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $29,000. Torren Management LLC bought a new position in Upstream Bio during the fourth quarter worth $30,000. BNP Paribas Financial Markets lifted its holdings in Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc boosted its position in Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Upstream Bio during the 4th quarter worth about $45,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UPB. HC Wainwright initiated coverage on Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $35.00 to $8.00 in a research note on Friday, June 12th. Mizuho reduced their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price on the stock. in a research report on Friday, March 27th. Finally, Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $33.17.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $7.51 on Friday. The stock’s 50 day moving average is $7.79 and its 200-day moving average is $14.62. Upstream Bio, Inc. has a twelve month low of $5.85 and a twelve month high of $33.68. The firm has a market capitalization of $408.69 million, a price-to-earnings ratio of -2.58 and a beta of 1.23.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Equities research analysts anticipate that Upstream Bio, Inc. will post -2.9 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.